MDA Space is not buying a smallsat company. The Canadian space-systems prime is paying $620 million in cash for a piece of paper it cannot print on its own: a U.S. defense license to operate, awarded by regulators, that lets a foreign-owned supplier bid on classified and prime work.
That license lives inside Blue Canyon Technologies (BCT), the Boulder, Colorado-based smallsat and smallsat-component builder that Raytheon parent RTX announced it will sell to MDA in an all-cash deal expected to close by year-end, subject to review by the Committee on Foreign Investment in the United States, or CFIUS.
MDA Space CEO Mike Greenley framed the deal as a U.S. foothold on the analyst call announcing it. The cleaner reading is that MDA is buying the right to be adjudicated as a U.S. prime by the Defense Counterintelligence and Security Agency (DCSA) and Treasury. BCT already has roughly 400 employees across two Colorado facilities, projected 2026 revenue of about $160 million (up from $115 million in 2023, per the trade-publication report on the deal), and what MDA executives described as approximately 75 percent defense revenue. That mix, more than the satellite buses, is the asset.
The mechanism that turns a foreign-owned factory into a U.S. prime is FOCI: Foreign Ownership, Control, or Influence mitigation. Under a FOCI arrangement, a cleared U.S. subsidiary operates under a proxy agreement, a board resolution, or a voting trust that puts a designated U.S. citizen in charge of security decisions and isolates classified work from foreign-influenced management. Without that structure, a Canadian-owned BCT could keep building buses for unclassified Pentagon and commercial customers, but it could not touch the classified and prime-contract pipeline Greenley keeps talking about. CFIUS review, in this reading, is not a risk to the deal. It is the product.
Greenley said on the analyst call that BCT is already a "candidate member" of MDA's current supply chain, which opens a vertical-integration path: MDA-built payloads on BCT-built buses, or vice versa. He also said MDA has a "strong short list" of further U.S. and European targets and would not rule out additional deals, the second major space acquisition in roughly a year after the Israeli satellite-chip maker SatixFy.
The most analytically interesting party in the file is the seller. Greenley told analysts he did not know why RTX had decided to divest BCT, and RTX declined to comment on the sale decision. That silence is worth more than the $620 million price, because RTX is one of the few primes that has both the motive and the inside view to know whether smallsat buses are a strategic line of business or a non-core distraction it would rather monetize. The fact that RTX is letting BCT go without a public rationale, six years after buying it, leaves the door open to two readings: either BCT's growth and defense pedigree no longer fit RTX's portfolio shape, or the classified-contract pathway BCT unlocks is more valuable to MDA than it ever was to RTX. The market will not resolve that question until an RTX disclosure, an analyst note, or a follow-on deal forces the issue.
There are real caveats. The CFIUS outcome is not guaranteed; a Canadian acquirer of a U.S. defense smallsat supplier is exactly the case CFIUS is built to scrutinize, and the mitigation package BCT ends up under will determine which classified programs it can keep. The 2026 revenue figure is a projection, not realized revenue, and the 75 percent defense share is an approximation Greenley gave analysts rather than a filed disclosure. Treating the deal as a clean win for either side requires accepting MDA's strategic framing on MDA's terms, and Greenley's framing is the only on-record one in the file.
What to watch next: the CFIUS terms when they are published, the next name on MDA's short list, and whether any RTX disclosure or analyst note explains what BCT was worth inside RTX, and what it stopped being worth in 2026.